Source: CNN Health
Published 7:02 PM EST, Tue January 16, 2024
Read more: https://www.cnn.com/2024/01/16/health/c ... index.htmlCNN — The US Food and Drug Administration has approved a second use for the first CRISPR-based medicine, Casgevy, which was approved in December to treat sickle cell disease.
The groundbreaking treatment can now also be used to treat transfusion-dependent beta thalassemia in people 12 and older. Like sickle cell, beta thalassemia is an inherited blood disorder. The FDA’s decision was expected, but it comes about two months earlier than the agency’s deadline for acting, called the PDUFA date.
To make Casgevy, a person’s stem cells are genetically modified using a precision gene editing technique called CRISPR/Cas9. The modified cells are then transplanted back into the body, where they grow and multiply and increase the production of hemoglobin, which decreases symptoms. The treatment lists for $2.2 million for both sickle cell disease and beta thalassemia.
“Today’s approval is an important step in the advancement of an additional treatment option for individuals with beta-thalassemia, a debilitating disease that places individuals at risk of many serious health problems,” said Dr. Nicole Verdun, director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research, in a news release.